CD19 and neoplasm: Remarkably, in mice engrafted with B-ALL, an initial regimen of cyclophosphamide coupled with fludarabine, followed by CD19 CAR-T cell therapy on the fifth day, manifested superior efficacy in both diminishing tumor mass and enhancing survival rates (Figs. 1B–1D).